Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Orexo AB ( (SE:ORX) ) just unveiled an announcement.
Orexo AB has announced the appointment of its Nomination Committee for the Annual General Meeting scheduled for May 7, 2026. The committee, representing approximately 34% of the company’s voting power, includes members from Novo Holdings, The Danish Labour Market Supplementary Pension, and private investors. This strategic move ensures diverse representation and stakeholder engagement in Orexo’s governance, potentially impacting its future strategic decisions.
The most recent analyst rating on (SE:ORX) stock is a Hold with a SEK23.00 price target. To see the full list of analyst forecasts on Orexo AB stock, see the SE:ORX Stock Forecast page.
More about Orexo AB
Orexo is a Swedish pharmaceutical company with 30 years of experience in developing improved pharmaceuticals using proprietary formulation technologies. The company focuses on providing innovative treatment solutions for opioid use disorder in the US market and collaborates with leading partners to develop products for other therapeutic areas globally. In 2024, Orexo reported net sales of SEK 590 million and employed 110 people. It is listed on Nasdaq Stockholm and available as ADRs on the OTCQX market in the US.
Average Trading Volume: 60,955
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.3B
For an in-depth examination of ORX stock, go to TipRanks’ Overview page.